Abstract 3219
Background
Individuals newly diagnosed with cancer may experience impairments in several aspects of health and often have a high need for both information and support. Approximately 30 % will experience symptoms of anxiety and depression with varying needs of support. E-health interventions such as internet-based interactive health communication applications (IHCAs) may offer a supplement to standard care services. Developers of such interventions need to work closely with presumptive users to add relevance and value. The purpose was to explore the user experiences of an IHCA targeting individuals with breast- colorectal or prostate cancer with symptoms of anxiety and depression.
Methods
A qualitative study with inductive approach was conducted, where 15 individuals using an IHCA targeting symptoms of anxiety and depression were interviewed with semi-structured questions. Content analysis was used to analyze interviews.
Results
The need for information was described as high, and almost looked upon as a survival strategy when newly diagnosed. The IHCA was experienced as a useful, reliable source of information and support, and was used as a complement to standard care. Increased knowledge was a foundation for continued processing of own feelings and the favorable time to get access to the IHCA was when being informed of the diagnose. The common denominator was that of being acknowledged but with a further desire for individual adjustment to own situation and needs.
Conclusions
The IHCA was experienced as a safe and reliable complement to standard care. Similar interventions may gain from a more individualized content, being integrated in to standard care and/or by using tracking of symptoms to adjust the content. Offering the IHCA closer to diagnosis may provide more benefits to users.
Clinical trial identification
NCT-01630681.
Editorial acknowledgement
Legal entity responsible for the study
Regional Committee for Research Ethics Sweden, Uppsala county (Dnr 2012/003/9).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract